Autor: |
Smeele HT; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands., Perez-Garcia LF; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands., Grimminck K; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Gynaecology and Obstetrics, Reiner de Graaf Gasthuis, Delft, The Netherlands., Schoenmakers S; Department of Gynaecology and Obstetrics, Erasmus University Medical Center, Rotterdam, The Netherlands., Mulders AG; Department of Gynaecology and Obstetrics, Erasmus University Medical Center, Rotterdam, The Netherlands., Dolhain RJ; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands. |
Abstrakt: |
Background: The ongoing corona virus disease 2019 (COVID-19) pandemic is having a worldwide impact. Valuable information on the clinical characteristics of COVID-19 in pregnant patients with an autoimmune disease, such as systemic lupus erythematosus (SLE), is currently lacking. Methods: Herein, we describe the clinical presentation of 2 pregnant patients with SLE and mild symptomatic COVID-19 infection. Results: In both pregnant SLE patients, a watchful-waiting approach without initiation of treatment for COVID-19 was taken. No adverse outcomes were reported and both pregnancies resulted in healthy neonates born at term. In one patient we observed a flare in SLE disease activity, most likely attributed to discontinuing SLE treatment. Conclusion: Our report highlights the importance of multidisciplinary collaboration between health care professionals as well as individualized treatment decisions during unprecedented periods such as the current COVID-19 pandemic. Discontinuation of immunosuppressive drugs during the acute phase of a COVID-19 infection should be considered on a case-by-case basis. Maternal treatment decisions should be in line with current recommendations for treatment of rheumatic and musculoskeletal diseases during COVID-19 infection and in line with treatment of COVID- 19 during pregnancy. |